Company: APM
Filing Date: 2025-11-17
Form Type: F-1
Source: 0001213900-25-111548
Chunk: 9

Company: Aptorum Group Ltd
Filing Date: 2025-11-17
Form: F-1
Chunk 9
---
 this prospectus refer to Hong Kong Special Administrative Region of the People’s Republic of China. All references to the “United States,” “U.S.” or “US” refer to the United States of America. Unless otherwise noted in this prospectus, disclosure herein including disclosure incorporated by reference herein pertains to Aptorum Group Limited, a Cayman Islands exempted company with limited liability. i SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This prospectus, including the sections titled “Prospectus Summary,” “Risk Factors,” “Our Business,” and “Operating and Financial Review and Prospects” as well as information we incorporated herein by reference, contains forward-looking statements that are based on our management’s belief and assumptions and on information currently available to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements in this prospectus and the documents incorporated herein by reference include, but are not limited to, statements about:

| ● | the initiation, timing, progress and results of our preclinical and clinical trials, and our research and development programs; |

| ● | our ability to advance our drug candidates into, and successfully complete, clinical trials; |

| ● | our ability to identify and develop new drug and device candidates; |

| ● | our reliance on the success of our drug candidates currently undergoing preclinical development; in particular, our Lead Project candidates; |

| ● | the timing or likelihood of regulatory filings and approvals; |

| ● | the commercialization of our drug and device candidates, if approved; |

| ● | our ability to develop sales and marketing capabilities; |

| ● | the pricing and reimbursement of our drug candidates, if approved; |

| ● | the implementation of our business model, strategic plans for our business and technology; |

| ● | the scope of protection we are able to establish and maintain for IP rights covering our drug and device candidates and technology; |

| ● | our ability to operate our business without infringing the IP rights and proprietary technology of other parties; |

| ● | costs associated with defending IP infringement, product liability and other claims; |

| ● | regulatory development in the U.S., Europe and PRC and other jurisdictions; |

| ●